Pfizer 2026: Transition Year with a Clear Strategic Agenda

Pfizer is deliberately marking the year 2026 as a year of transition. Following the extraordinary COVID cycle, the company is entering a phase where multiple stress factors are at play simultaneously. Decreasing pandemic-related revenues, a noticeable patent cliff beginning in 2026, and high investments in new therapy fields characterize the landscape. Management has made it clear that 2026 should not be a year of operational surprises, but rather one for stabilization, preparation, and strategic decision-making with a view toward the end of the...